Kimberly E. Resnick, MD | The ...

Dr. Kimberly E. Resnick

Claim this profile

MetroHealth Medical Center

Studies Ovarian Cancer
Studies Cervical Cancer
9 reported clinical trials
24 drugs studied

Area of expertise

1

Ovarian Cancer

Kimberly E. Resnick has run 4 trials for Ovarian Cancer. Some of their research focus areas include:

BRCA1 positive
Stage II
Stage III
2

Cervical Cancer

Kimberly E. Resnick has run 3 trials for Cervical Cancer. Some of their research focus areas include:

Stage IV
Stage III
Stage II

Affiliated Hospitals

Image of trial facility.

MetroHealth Medical Center

Clinical Trials Kimberly E. Resnick is currently running

Image of trial facility.

Herceptin Hylecta or Phesgo + Chemotherapy

for Uterine Cancer

This phase III trial tests whether adding trastuzumab and hyaluronidase-oysk (Herceptin Hylecta \[TM\]) or pertuzumab, trastuzumab and hyaluronidase-zzxf (Phesgo \[TM\]) to the usual chemotherapy (paclitaxel and carboplatin) works to shrink tumors in patients with HER2 positive endometrial cancer. Trastuzumab and pertuzumab are monoclonal antibodies and forms of targeted therapy that attach to specific molecules (receptors) on the surface of tumor cells, known as HER2 receptors. When trastuzumab or pertuzumab attach to HER2 receptors, the signals that tell the cells to grow are blocked and the tumor cell may be marked for destruction by the body's immune system. Hyaluronidase is an endoglycosidase. It helps to keep pertuzumab and trastuzumab in the body longer, so that these medications will have a greater effect. Hyaluronidase also allows trastuzumab and trastuzumab/pertuzumab to be given by injection under the skin and shortens their administration time compared to trastuzumab or pertuzumab alone. Paclitaxel is a taxane and in a class of medications called antimicrotubule agents. It stops tumor cells from growing and dividing and may kill them. Carboplatin is in a class of medications known as platinum-containing compounds. It works in a way similar to the anticancer drug cisplatin, but may be better tolerated than cisplatin. Carboplatin works by killing, stopping or slowing the growth of tumor cells. Giving Herceptin Hylecta or Phesgo in combination with paclitaxel and carboplatin may shrink the tumor and prevent the cancer from coming back in patients with HER2 positive endometrial cancer.

Recruiting

2 awards

Phase 3

Image of trial facility.

Surgical Procedures

for Reducing Ovarian Cancer Risk

This clinical trial evaluates how well two surgical procedures (bilateral salpingectomy and bilateral salpingo-oophorectomy) work in reducing the risk of ovarian cancer for individuals with BRCA1 mutations. Bilateral salpingectomy involves the surgical removal of fallopian tubes, and bilateral salpingo-oophorectomy involves the surgical removal of both the fallopian tubes and ovaries. This study may help doctors determine if the two surgical procedures are nearly the same for ovarian cancer risk reduction for women with BRCA1 mutations.

Recruiting

1 award

N/A

More about Kimberly E. Resnick

Clinical Trial Related

5 years of experience running clinical trials · Led 9 trials as a Principal Investigator · 2 Active Clinical Trials

Treatments Kimberly E. Resnick has experience with

  • Paclitaxel
  • Cisplatin
  • Carboplatin
  • AGEN2034
  • AGEN1884
  • Topotecan

Other Doctors you might be interested in

Frequently asked questions

Do I need insurance to participate in a trial?

What does Kimberly E. Resnick specialize in?

Is Kimberly E. Resnick currently recruiting for clinical trials?

Are there any treatments that Kimberly E. Resnick has studied deeply?

What is the best way to schedule an appointment with Kimberly E. Resnick?

What is the office address of Kimberly E. Resnick?

Is there any support for travel costs?

Unbiased Results

We believe in providing patients with all the options.

Your Data Stays Your Data

We only share your information with the clinical trials you're trying to access.

Verified Trials Only

All of our trials are run by licensed doctors, researchers, and healthcare companies.

Terms of Service·Privacy Policy·Cookies·Security